GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (FRA:APS) » Definitions » Profitability Rank

Asarina Pharma AB (FRA:APS) Profitability Rank : 1 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Profitability Rank?

Asarina Pharma AB has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Asarina Pharma AB's Operating Margin % for the quarter that ended in Jun. 2023 was %. As of today, Asarina Pharma AB's Piotroski F-Score is 2.


Competitive Comparison of Asarina Pharma AB's Profitability Rank

For the Biotechnology subindustry, Asarina Pharma AB's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asarina Pharma AB's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asarina Pharma AB's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Asarina Pharma AB's Profitability Rank falls into.



Asarina Pharma AB Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Asarina Pharma AB has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Asarina Pharma AB's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=0 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Asarina Pharma AB has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Asarina Pharma AB Profitability Rank Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Asarina Pharma AB (FRA:APS) Business Description

Traded in Other Exchanges
Address
Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (FRA:APS) Headlines

No Headlines